HLA Class-II Restricted DRB T-cell Receptors Against The RASG12D Mutation Read more about HLA Class-II Restricted DRB T-cell Receptors Against The RASG12D Mutation Patent Cooperation TreatyPCT/US2021/041375Filed on 2021-07-13
Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation Read more about Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation European Patent22166152.3Filed on 2022-03-31
USE OF ISOVALERYLSPIRAMYCINS AS ANTI-CANCER AGENTS TO INHIBIT METASTASIS Read more about USE OF ISOVALERYLSPIRAMYCINS AS ANTI-CANCER AGENTS TO INHIBIT METASTASIS Patent Cooperation TreatyPCT/US2021/021831Filed on 2021-03-11
High-Affinity Fully Functional Soluble Single-Domain Human CD4, Antibodies, and Related Fusion Proteins Read more about High-Affinity Fully Functional Soluble Single-Domain Human CD4, Antibodies, and Related Fusion Proteins European Patent21185510.1Filed on 2021-07-14
IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF Read more about IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF European Patent19865927.8Filed on 2019-09-30
MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE Read more about MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE US Application 17/306,756Filed on 2021-05-03
SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM Read more about SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM Patent Cooperation TreatyPCT/US2021/036548Filed on 2021-06-09
TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER Read more about TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER US Application 17/294,011Filed on 2021-05-14
TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER Read more about TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER European Patent19817052.4Filed on 2021-06-10
TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER Read more about TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER Canada3119736Filed on 2021-05-12